{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:47:50Z","timestamp":1792838870380,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:00:00Z","timestamp":1701475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.rpth.2023.102293","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T18:25:19Z","timestamp":1702146319000},"page":"102293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Venous thromboembolism, chronic liver disease and anticoagulant choice: effectiveness and safety of direct oral anticoagulants versus warfarin"],"prefix":"10.1016","volume":"8","author":[{"given":"Oluwadolapo D.","family":"Lawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert D.","family":"Aronow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne L.","family":"Hume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fisayomi","family":"Shobayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L.","family":"Matson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"Barbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuerong","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2023.102293_bib1","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(11)61904-1","article-title":"Pulmonary embolism and deep vein thrombosis","volume":"379","author":"Goldhaber","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2023.102293_bib2","doi-asserted-by":"crossref","first-page":"I4","DOI":"10.1161\/01.CIR.0000078468.11849.66","article-title":"The epidemiology of venous thromboembolism","volume":"107","author":"White","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2023.102293_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3949\/ccjm.84.s3.04","article-title":"Update on the management of venous thromboembolism","volume":"84","author":"Bartholomew","year":"2017","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.rpth.2023.102293_bib4","unstructured":"Centers for Disease Control and Prevention. Data and statistics on venous thromboembolism. https:\/\/www.cdc.gov\/ncbddd\/dvt\/data.html; 2020. [accessed September 28, 2021]."},{"key":"10.1016\/j.rpth.2023.102293_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.rpth.2023.102293_bib6","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","article-title":"Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST Guideline and Expert Panel Report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.rpth.2023.102293_bib7","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2023.102293_bib8","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.jacc.2018.03.023","article-title":"Oral anticoagulation in patients with liver disease","volume":"71","author":"Qamar","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2023.102293_bib9","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","article-title":"Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction","volume":"69","author":"Yao","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2023.102293_bib10","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaccao.2021.06.004","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients with active cancer","volume":"3","author":"Deitelzweig","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.rpth.2023.102293_bib11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhepr.2019.02.006","article-title":"Anticoagulation in the cirrhotic patient","volume":"1","author":"Turco","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.rpth.2023.102293_bib12","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2023.102293_bib13","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2023.102293_bib14","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"B\u00fcller","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2023.102293_bib15","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2023.102293_bib16","first-page":"1491","article-title":"Faculty of the 7th International Coagulation in Liver Disease. Concepts and controversies in haemostasis and thrombosis associated with liver disease: Proceedings of the 7th International Coagulation in Liver Disease Conference","volume":"118","author":"Intagliata","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.102293_bib17","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s10620-015-4012-2","article-title":"Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation","volume":"61","author":"Intagliata","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.rpth.2023.102293_bib18","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.thromres.2015.01.012","article-title":"Improving accuracy of International Classification of Diseases codes for venous\u00a0thromboembolism in administrative data","volume":"135","author":"Sanfilippo","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2023.102293_bib19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.thromres.2010.03.009","article-title":"Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States","volume":"126","author":"White","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2023.102293_bib20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/pds.2341","article-title":"A\u00a0systematic review of validated methods for identifying venous thromboembolism using administrative and claims data","volume":"21","author":"Tamariz","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.rpth.2023.102293_bib21","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/hep.31726","article-title":"Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement","volume":"74","author":"Hagstr\u00f6m","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.rpth.2023.102293_bib22","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.29546","article-title":"Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study","volume":"67","author":"Allen","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.rpth.2023.102293_bib23","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1055\/s-0038-1673689","article-title":"Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in U.S. clinical practice","volume":"118","author":"Weycker","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.102293_bib24","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1097\/MLR.0000000000000524","article-title":"Validity of using inpatient and outpatient administrative codes to identify acute venous thromboembolism: the CVRN VTE study","volume":"55","author":"Fang","year":"2017","journal-title":"Med Care"},{"key":"10.1016\/j.rpth.2023.102293_bib25","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/pds.4783","article-title":"Assessment of ICD-10-CM code assignment validity for case finding of outpatient anticoagulant-related bleeding among Medicare beneficiaries","volume":"28","author":"Shehab","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.rpth.2023.102293_bib26","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/pds.2109","article-title":"An automated database case definition for serious bleeding related to oral anticoagulant use","volume":"20","author":"Cunningham","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.rpth.2023.102293_bib27","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/aje\/kwn404","article-title":"The impact on National Death Index ascertainment of limiting submissions to social security administration Death Master File matches in epidemiologic studies of mortality","volume":"169","author":"Hermansen","year":"2009","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.rpth.2023.102293_bib28","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCOUTCOMES.112.968826","article-title":"Consequences for healthcare quality and research of the exclusion of records from the Death Master File","volume":"6","author":"da Graca","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.rpth.2023.102293_bib29","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s40264-019-00827-0","article-title":"Identifying the DEAD: development and validation of a patient-level model to predict death status in population-level claims data","volume":"42","author":"Reps","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.rpth.2023.102293_bib30","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.102293_bib31","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.102293_bib32","unstructured":"US Food and Drug Administration. Drug development and drug interactions. Table\u00a0of substrates, inhibitors and inducer. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers; 2021. [accessed December 4, 2021]."},{"key":"10.1016\/j.rpth.2023.102293_bib33","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2023.102293_bib34","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A\u00a0novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.rpth.2023.102293_bib35","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring frailty in medicare data: development and validation of a claims-based frailty index","volume":"73","author":"Kim","year":"2018","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.rpth.2023.102293_bib36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"10.1016\/j.rpth.2023.102293_bib37","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/MCG.0b013e3182688d2f","article-title":"Use of administrative claims data for identifying patients with cirrhosis","volume":"47","author":"Nehra","year":"2013","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.rpth.2023.102293_bib38","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/pds.2148","article-title":"Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study","volume":"20","author":"Lo Re","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.rpth.2023.102293_bib39","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/hep.24616","article-title":"Burden of cirrhosis on older Americans and their families: analysis of the health and retirement study","volume":"55","author":"Rakoski","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.rpth.2023.102293_bib40","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1007\/s12325-020-01307-z","article-title":"Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: a narrative review","volume":"37","author":"Ballestri","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.rpth.2023.102293_bib41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3109\/03602532.2011.577781","article-title":"Drug metabolism alterations in nonalcoholic fatty liver disease","volume":"43","author":"Merrell","year":"2011","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.rpth.2023.102293_bib42","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/jth.13336","article-title":"Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH","volume":"14","author":"Kearon","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.102293_bib43","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","article-title":"High-dimensional propensity score adjustment in studies of treatment effects using health care claims data","volume":"20","author":"Schneeweiss","year":"2009","journal-title":"Epidemiology"},{"key":"10.1016\/j.rpth.2023.102293_bib44","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rpth.2023.102293_bib45","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"key":"10.1016\/j.rpth.2023.102293_bib46","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S2352-3026(18)30191-1","article-title":"Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis","volume":"6","author":"Dawwas","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2023.102293_bib47","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2023.102293_bib48","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2023.102293_bib49","doi-asserted-by":"crossref","first-page":"463","DOI":"10.7326\/M19-2522","article-title":"Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study","volume":"172","author":"Fralick","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rpth.2023.102293_bib50","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.7326\/M21-1474","article-title":"Rivaroxaban is associated with higher rates of gastrointestinal bleeding than other direct oral anticoagulants: a nationwide propensity score-weighted study","volume":"174","author":"Ingason","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rpth.2023.102293_bib51","first-page":"968","article-title":"Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation","volume":"23","author":"Adeboyeje","year":"2017","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.rpth.2023.102293_bib52","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/CIRCULATIONAHA.122.060687","article-title":"Comparative effectiveness and safety of direct oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: a nationwide cohort study","volume":"147","author":"Lawal","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2023.102293_bib53","first-page":"179","article-title":"A\u00a0randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban","volume":"6","author":"Frost","year":"2014","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.rpth.2023.102293_bib54","doi-asserted-by":"crossref","first-page":"18","DOI":"10.14309\/ajg.0000000000000486","article-title":"ACG Clinical Guideline: disorders of the hepatic and\u00a0mesenteric circulation","volume":"115","author":"Simonetto","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rpth.2023.102293_bib55","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/j.gastro.2019.03.070","article-title":"AGA Clinical Practice Update: coagulation in cirrhosis","volume":"157","author":"O\u2019Leary","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rpth.2023.102293_bib56","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.cgh.2020.08.007","article-title":"Rates of bleeding and discontinuation of direct oral anticoagulants in patients with decompensated cirrhosis","volume":"19","author":"Mort","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.rpth.2023.102293_bib58","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.seminhematol.2014.02.002","article-title":"Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding","volume":"51","author":"Palareti","year":"2014","journal-title":"Semin Hematol"},{"key":"10.1016\/j.rpth.2023.102293_bib59","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.jacc.2017.09.1087","article-title":"Renal outcomes in anticoagulated patients with atrial fibrillation","volume":"70","author":"Yao","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037923057217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037923057217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:32:47Z","timestamp":1762864367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037923057217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2475037923057217"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2023.102293","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venous thromboembolism, chronic liver disease and anticoagulant choice: effectiveness and safety of direct oral anticoagulants versus warfarin","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2023.102293","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102293"}}